

CLAIMS

1. A DNA transfer vector containing a sequence coding for a p185^{neu}-fragment, wherein said sequence is selected from the group consisting of SEQ ID N. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14.
2. A DNA transfer vector according to claim 1, which is a plasmid.
3. The plasmid of claim 2, further containing a transcription promotor.
4. The plasmid of claim 3, wherein the promotor is CMV.
5. The plasmid of claim 2, further containing 4 CpG motifs.
- 10 6. The plasmid of claim 5, further containing 8 CpG motifs.
7. Pharmaceutical composition containing a DNA transfer vector according to any one of claims 1-6 in admixture with pharmaceutically acceptable vehicles and excipients.
8. The composition according to claim 7, which is suitable for parenteral administration.
- 15 9. The composition of claim 8, which is in the form of injectable solution.
10. A combined pharmaceutical preparation containing at least two different plasmids according to claims 1-6, for simultaneous, sequential or separate therapeutic use.
- 20 11. A combined preparation according to claim 10, which is in a form suitable for DNA vaccination.
12. Use of a plasmid according to claims 1-6 to prepare a pharmaceutical composition for use in the preventive or therapeutical treatment of subjects at risk of developing p185^{neu} positive tumours, or of patients having primary tumours, metastasis or relapses of p185^{neu}-expressing tumours.
- 25 13. The use according to claim 12, for the preparation of a DNA vaccine.